Lilly's Q1 2026 revenue rose 56%; full-year guidance raised

Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56%, mainly from volume growth partly offset by lower realized prices. Mounjaro revenue rose 125% to $8.66 billion and Zepbound rose 80% to $4.16 billion. Lilly raised 2026 revenue guidance to $82 billion-$85 billion and non-GAAP EPS guidance to $35.50-$37.00.

• Q1 2026 revenue $19.8B, up 56%
• Mounjaro $8,662M (up 125%); Zepbound $4,160M (up 80%)
• Reported EPS $8.26 (up 170%); non-GAAP EPS $8.55 (up 156%)
• 2026 guidance raised: revenue $82B-$85B, non-GAAP EPS $35.50-$37.00

SEC filing 8-K · accession 0000059478-26-000043 · sec.gov ↗